A study of patchy hair loss(alopecia areata) by local examination and using an instrument (dermoscope) and a study of effectiveness of an applicant called Diphenycyprone

A clinico-trichoscopic study of alopecia areata and therapeutic response of topical immunotherapy using Diphencyprone in refractory cases involving the scalp - ALODIP

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2019/04/018380

Enrollment

Registered

2019-04-02

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L639- Alopecia areata, unspecified Health Condition 2: L639- Alopecia areata, unspecified

Interventions

Intervention1: DIPHENCYPRONE: TOPICAL IMMUNOTHERAPY AGENT Concentrations of 2%, 0.001%, 0.01%, 0.5% and 1% will be applied topically Total duration of treatment - 12 weeks

Eligibility

Inclusion criteria

Inclusion criteria: All patients visiting Yenepoya medical college hospital during the study period with a clinical diagnosis of alopecia areata voluntarily consenting to participate in the study For the Diphencyprone treatment group: Patients who have failed any one form of treatment for alopecia areata and those willing for regular follow up.

Exclusion criteria

Exclusion criteria: Patient with immunocompromised status, pregnancy, lactating mothers, severe systemic illnesses

Design outcomes

Primary

Measure	Time frame
1. Determining clinical profile of Alopecia areata 2. Determining the Dermoscopic featuresTimepoint: 18 months	—

Secondary

Measure	Time frame
Efficacy of Diphencyprone in Alopecia areataTimepoint: 12 WEEKS	—

Countries

India

Contacts

Public ContactSMERA RAMAKRISHNAN

YENEPOYA MEDICAL COLLEGE

manjunath576117@yahoo.co.in7619636516

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026